Nanobiotix Email Format

Nanotechnology ResearchÎle-de-france, France51-200 Employees

Nanobiotix is a mid-sized, late-stage biotechnology company focused on nanotherapeutics aimed at expanding cancer treatment options. Its lead candidate, NBTXR3, is designed to boost the impact of radiotherapy on tumors while limiting harm to healthy tissue, and it is being explored for use with immune-based therapies. The firm is also advancing a second platform intended to improve systemic drug delivery and efficacy.

Headquartered in Paris, in the Île-de-France region, with a U.S. affiliate in Cambridge, Massachusetts, Nanobiotix was founded in 2003. Its customers include clinicians and healthcare systems seeking novel radiation-enhancing therapies to improve cancer outcomes for patients. In June 2026, Nanobiotix joined the Euronext Tech Leaders Index, signaling recognition within Europe’s technology-focused markets.

Sign up for free to view info

Company overview Employee directory